Celea Therapeutics secures $180M financing to advance IPF pipeline
read at Endpoints ↗DealNeutral
Celea Therapeutics, an idiopathic pulmonary fibrosis (IPF) biotech, announced it has raised $180 million from a group of new investors.
The funding is intended to help the company follow the development trajectories of its PureTech Health sister companies, Karuna Therapeutics and Seaport Therapeutics.
With the capital, Celea plans to advance its own IPF drug candidates through preclinical and early clinical stages.
The announcement was made by PureTech Health CEO Robert Lyne on July 2, 2026.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport”
read at Endpoints ↗88 words · retrieved Jul 2
comments(0)
5-min edit window · permanent after that